Simple Summary Positron emission tomography (PET) is a functional imaging technique
which plays an increasingly important role in the management of brain tumors. Owing …

Meningiomas are the most common primary intracranial tumors in adults and are increasing
in incidence due to the aging population and increased access to neuroimaging. While most …

Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …

Purpose To provide practice guideline/procedure standards for diagnostics and therapy
(theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands …

Purpose There is no evidence-based systemic therapy for patients with progressive
meningiomas for whom surgery or external radiotherapy is no longer an option. In this study …

Introduction Meningiomas are associated with several gonadal steroid hormone-related risk
factors and demonstrate a predominance in females. These associations led to …

Theranostics integrate molecular imaging and targeted radionuclide therapy for
personalised cancer therapy. Theranostic treatments have shown meaningful efficacy in …

Benign tumors that grow in the spinal canal are heterogeneous neoplasms with low
incidence; from these, meningiomas and nerve sheath tumors (neurofibromas and …

Despite a low evidence level, some systemic therapies may be considered for patients with
recurrent meningioma not amenable to further surgery or radiotherapy. In recurrent high …

Objectives Tumor dosimetry with somatostatin receptor–targeted peptide receptor
radionuclide therapy (SSTR-targeted PRRT) by 177Lu-DOTATATE may contribute to …